Patient-reported outcomes after surgery for endometrial carcinoma: Prevalence of lower-extremity lymphedema after sentinel lymph node mapping versus lymphadenectomy.
Adult
Aged
Aged, 80 and over
Endometrial Neoplasms
/ epidemiology
Female
Humans
Leg
/ pathology
Lymph Node Excision
/ adverse effects
Lymph Nodes
/ pathology
Lymphatic Metastasis
Lymphedema
/ epidemiology
Middle Aged
Patient Reported Outcome Measures
Postoperative Complications
/ epidemiology
Prevalence
Sentinel Lymph Node
/ pathology
Sentinel Lymph Node Biopsy
/ adverse effects
Surveys and Questionnaires
Endometrial cancer
Lymphadenectomy
Lymphedema
Patient-reported outcomes
Sentinel lymph node
Sentinel lymph node mapping
Journal
Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
03
09
2019
revised:
31
10
2019
accepted:
02
11
2019
pubmed:
30
11
2019
medline:
25
2
2020
entrez:
30
11
2019
Statut:
ppublish
Résumé
To compare the prevalence of patient-reported lower-extremity lymphedema (LEL) with sentinel lymph node (SLN) mapping versus comprehensive lymph node dissection (LND) for the surgical management of newly diagnosed endometrial carcinoma. Patients who underwent primary surgery for endometrial cancer from 01/2006-12/2012 were mailed a survey that included a validated 13-item LEL screening questionnaire in 08/2016. Patients diagnosed with LEL prior to surgery and those who answered ≤6 survey items were excluded. Of 1275 potential participants, 623 (49%) responded to the survey and 599 were evaluable (180 SLN, 352 LND, 67 hysterectomy alone). Median BMI was similar among cohorts (P = 0.99). External-beam radiation therapy (EBRT) was used in 10/180 (5.5%) SLN and 35/352 (10%) LND patients (P = 0.1). Self-reported LEL prevalence was 27% (49/180) and 41% (144/352), respectively (OR, 1.85; 95% CI, 1.25-2.74; P = 0.002). LEL prevalence was 51% (23/45) in patients who received EBRT and 35% (170/487) in those who did not (OR, 1.95; 95% CI, 1.06-3.6; P = 0.03). High BMI was associated with increased prevalence of LEL (OR, 1.04; 95% CI, 1.02-1.06; P = 0.001). After controlling for EBRT and BMI, LND retained independent association with an increased prevalence of LEL over SLN (OR, 1.8; 95% CI, 1.22-2.69; P = 0.003). Patients with self-reported LEL had significantly worse QOL compared to those without self-reported LEL. This is the first study to assess patient-reported LEL after SLN mapping for endometrial cancer. SLN mapping was independently associated with a significantly lower prevalence of patient-reported LEL. High BMI and adjuvant EBRT were associated with an increased prevalence of patient-reported LEL.
Identifiants
pubmed: 31780238
pii: S0090-8258(19)31624-5
doi: 10.1016/j.ygyno.2019.11.003
pmc: PMC6980687
mid: NIHMS1544572
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
147-153Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.
Références
J Clin Oncol. 2006 Jan 1;24(1):36-44
pubmed: 16330675
Gynecol Oncol. 2013 Sep;130(3):452-6
pubmed: 23774300
Gynecol Oncol. 2018 Nov;151(2):235-242
pubmed: 30177461
Gynecol Oncol. 1996 Aug;62(2):169-73
pubmed: 8751545
Gynecol Oncol. 2006 Nov;103(2):714-8
pubmed: 16740298
Lancet Oncol. 2017 Mar;18(3):384-392
pubmed: 28159465
J Clin Oncol. 2012 Nov 1;30(31):3786-91
pubmed: 22753905
J Clin Oncol. 2008 Feb 20;26(6):884-9
pubmed: 18281661
J Clin Epidemiol. 2016 Jan;69:79-88
pubmed: 26327487
Lancet. 2009 Jan 10;373(9658):125-36
pubmed: 19070889
Gynecol Oncol. 2010 May;117(2):317-23
pubmed: 20163847
Gynecol Oncol. 2012 Jun;125(3):531-5
pubmed: 22366409
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Stat Methods Med Res. 2010 Feb;19(1):53-70
pubmed: 19654168
Gynecol Oncol. 2017 Aug;146(2):234-239
pubmed: 28528918
Gynecol Oncol. 2016 Mar;140(3):394-9
pubmed: 26747778
Obstet Gynecol. 2014 Aug;124(2 Pt 1):307-15
pubmed: 25004343
Gynecol Oncol. 2014 Aug;134(2):385-92
pubmed: 24905773
J Natl Cancer Inst. 2008 Dec 3;100(23):1707-16
pubmed: 19033573
Public Opin Q. 2015 Summer;79(2):420-442
pubmed: 26120203
Gynecol Oncol. 2012 Apr;125(1):87-93
pubmed: 22155678
Phys Ther. 2013 May;93(5):694-703
pubmed: 23288911
Eur J Cancer. 2011 Jan;47(2):183-90
pubmed: 20851597
Gynecol Oncol. 2018 Mar;148(3):491-498
pubmed: 29273307